Development of the novel biologically targeted anticancer agent gefitinib: Determining the optimum dose for clinical efficacyWOLF, Michael; SWAISLAND, Helen; AVERBUCH, Steven et al.Clinical cancer research. 2004, Vol 10, Num 14, pp 4607-4613, issn 1078-0432, 7 p.Article

ZD1839 ('Iressa')^1,2 as an anticancer agentBASELGA, José; AVERBUCH, Steven D.Drugs (Basel). 2000, Vol 60, pp 33-40, issn 0012-6667, SUP1Article

Therapeutic potential of tyrosine kinase inhibitors in breast cancerAVERBUCH, Steven; KCENLER, Mana; MORRIS, Charles et al.Cancer investigation. 2003, Vol 21, Num 5, pp 782-791, issn 0735-7907, 10 p.Article

Multi-institutional randomized phase II trial of Gefitinib for previously treated patients with advanced non-small-cell lung cancerFUKUOKA, Masahiro; YANO, Seiji; EEK, Richard et al.Journal of clinical oncology. 2003, Vol 21, Num 12, pp 2237-2246, issn 0732-183X, 10 p.Article

The tyrosine kinase inhibitor ZD1839 (iressa) inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cellsMOASSER, Mark M; BASSO, Andrea; AVERBUCH, Steven D et al.Cancer research (Baltimore). 2001, Vol 61, Num 19, pp 7184-7188, issn 0008-5472Article

Gefitinib: Phase II and III results in advanced non-small cell lung cancerKELLY, Karen; AVERBUCH, Steven.Seminars in oncology. 2004, Vol 31, Num 1, pp 93-99, issn 0093-7754, 7 p., SUP1Article

Treatment of Malignant Pheochromocytoma/ Paraganglioma With Cyclophosphamide, Vincristine, and Dacarbazine : Recommendation From a 22-Year Follow-up of 18 PatientsHUI HUANG; ABRAHAM, Jame; HUNG, Elizabeth et al.Cancer. 2008, Vol 113, Num 8, pp 2020-2028, issn 0008-543X, 9 p.Article

Distribution and function of EGFR in human tissue and the effect of EGFR tyrosine kinase inhibitionYANO, Seiichi; KONDO, Kaoru; YAMAGUCHI, Motonori et al.Anticancer research. 2003, Vol 23, Num 5A, pp 3639-3650, issn 0250-7005, 12 p.Article

Making the Investigational Oncology Pipeline More Efficient and Effective: Are We Headed in the Right Direction? : Improving Outcomes in OncologyLORUSSO, Patricia M; ANDERSON, Aparna B; BOERNER, Scott A et al.Clinical cancer research (Print). 2010, Vol 16, Num 24, pp 5956-5962, issn 1078-0432, 7 p.Article

Translating Clinical Trials into Meaningful Outcomes : Improving Outcomes in OncologyLORUSSO, Patricia M; SCHNIPPER, Lowell E; STEWART, David J et al.Clinical cancer research (Print). 2010, Vol 16, Num 24, pp 5951-5955, issn 1078-0432, 5 p.Article

Evidence for the epidermal growth factor receptor as a target for lung cancer prevention. EditorialLONARDO, Fulvio; DRAGNEV, Konstantin H; FREEMANTLE, Sarah J et al.Clinical cancer research. 2002, Vol 8, Num 1, pp 54-60, issn 1078-0432, 10 p.Article

Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: Results of a phase I trialHERBST, Roy S; MADDOX, Anne-Marie; OCHS, Judith et al.Journal of clinical oncology. 2002, Vol 20, Num 18, pp 3815-3825, issn 0732-183X, SUPArticle

Improvements in quality of life and disease-related symptoms in Phase I trials of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in non-small cell Lung Cancer and other solid tumorsLORUSSO, Patricia M; HERBST, Roy S; BJORK, Thomas et al.Clinical cancer research. 2003, Vol 9, Num 6, pp 2040-2048, issn 1078-0432, 9 p.Article

Efficacy of Gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic Patients with non-small cell lung Cancer a randomized trialKRIS, Mark G; NATALE, Ronald B; ALBAIN, Kathy S et al.JAMA, the journal of the American Medical Association. 2003, Vol 290, Num 16, pp 2149-2158, issn 0098-7484, 10 p.Article

Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: A phase III Trial-INTACT 1GIACCONE, Giuseppe; HERBST, Roy S; GATZEMEIER, Ulrich et al.Journal of clinical oncology. 2004, Vol 22, Num 5, pp 777-784, issn 0732-183X, 8 p.Article

Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: A phase III Trial-INTACT 2HERBST, Roy S; GIACCONE, Giuseppe; WOLF, Michael K et al.Journal of clinical oncology. 2004, Vol 22, Num 5, pp 785-794, issn 0732-183X, 10 p.Article